BioSpace News Archive

Nephros SequaPath™, a new microbial screening system, used to evaluate 88 building water samples across four US geographic regions

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced that a Fortune 100 global consumer packaged goods (CPG) company has deployed the LabVantage COVID-19 LIMS solution to ensure employee health and safety in the workplace.

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that the Company and Fox Chase Chemical Diversity Center, Inc. (“FCCDC”) have amended an earlier collaborative research agreement related to antifungal drug discovery work. Under the amended terms, and in exchange for a six (6) percent fee tied to all potential future proceeds—including upfront payments, milestone payments an

AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has initiated its Phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI) with

Tivity Health, Inc. (Nasdaq: TVTY) today announced that its financial results for the second quarter ending June 30, 2020, will be released after market close on Wednesday, August 5, 2020, followed the same day by a conference call and live webcast scheduled for 5:00 p.m. ET

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that in connection with the appointment of Susan Altschuller, PhD as ImmunoGen’s Senior Vice President and Chief Financial Officer, the compensation committee of ImmunoGen’s Board of Directors granted to Dr. Altschuller non-qualified stock option awards under the ImmunoGen, Inc.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced the completion of dosing for the Phase 1 multiple ascending dose (“MAD”) clinical study for RGLS4326 in healthy volunteers.

Nutriband Inc., a Nevada Corporation has announced that the application for its ‘AVERSA’ Trademark in relation to its abuse deterrent technology and lead product candidate has passed the examination and third party opposition phase and the company expects to receive a notice of allowance in due time.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company has reached target patient enrollment for its Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA [(MIRROR) randomized controlled trial (RCT)]. MIRROR RCT is the largest randomized trial to evaluate the efficacy and safety of the concomitant use of KRYSTEXXA®

X-Chem, Inc. (X-Chem), the global leader in DNA-encoded small molecule library screening and drug discovery, announced today that it has met a key development milestone in its collaboration with Orexia Limited (Orexia), a company focused on developing orexin positive modulators using unique structure based drug design capabilities.